Analyzing Telomir Pharmaceuticals (TELO) & The Competition

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,069 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Telomir Pharmaceuticals to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations.

Profitability

This table compares Telomir Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Ratings

This is a breakdown of current ratings for Telomir Pharmaceuticals and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8323	22118	50203	1341	2.54

Telomir Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 231.13%. As a group, “Pharmaceutical preparations” companies have a potential upside of 202.19%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Telomir Pharmaceuticals is more favorable than its peers.

Earnings and Valuation

This table compares Telomir Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-7.81
Telomir Pharmaceuticals Competitors	$9.93 billion	$136.87 million	-7.77

Telomir Pharmaceuticals’ peers have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Telomir Pharmaceuticals peers beat Telomir Pharmaceuticals on 8 of the 12 factors compared.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.